On June 30, 2025, Inmune Bio, Inc. announced positive topline results from its Phase 2 MINDFuL trial for XPro™ in early Alzheimer's patients and released an updated corporate presentation.
AI Assistant
INMUNE BIO INC
2025
8 K
Find Answers
Ask about any part of the document to get insights, explanations, or key details.